Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 8 mechanisms across 40 industry trials with a known mechanism of action.

See full pipeline →

Calcitonin Gene-related Peptide Receptor Antagonist

22 trials 7 active 2 sponsors

Acetylcholine Release Inhibitor

6 trials 2 active 2 sponsors

Cytochrome P450 3A4 Inducers [MoA]

2 trials 1 active 2 sponsors

Serotonin-1b and Serotonin-1d Receptor Agonist

5 trials 4 sponsors

5-HT 1B receptor/5-HT 1D receptor

2 trials 1 sponsor

5-HT1B/5-HT1D/COX-1/COX-2

1 trials 1 sponsor

Nonsteroidal Anti-inflammatory Drug

1 trials 1 sponsor

5-HT1B/5-HT1D

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

305 industry-sponsored trials across 77 sponsors

View full landscape →

Showing 39 of 39 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Upsher-Smith Laboratories	Qudexy XR	Cytochrome P450 3A4 Inducers [MoA]	RECRUITING	2026-09	NCT04748601
Alasht Pharmed	—	—	RECRUITING	2025-09-16	NCT07093138
H. Lundbeck A/S	Eptinezumab	—	ACTIVE NOT RECRUITING	2026-06-05	NCT06701526
Theranica	—	—	ACTIVE NOT RECRUITING	2026-01-20	NCT07336056
Theranica	—	—	COMPLETED	2026-01-25	NCT07336420
Theranica	—	—	COMPLETED	2025-06-10	NCT06976723
Pfizer	Rimegepant	—	COMPLETED	2025-03-31	NCT05518123
Pfizer	Rimegepant	—	COMPLETED	2025-03-10	NCT05509400
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2024-10-22	NCT05452239
Pfizer	Rimegepant 75mg daily dosing	—	COMPLETED	2024-10-22	NCT05217927
Pfizer	Rimegepant	—	COMPLETED	2024-07-02	NCT05207865
Amgen	Erenumab	—	COMPLETED	2023-10-26	NCT04252742
Amgen	Erenumab	—	COMPLETED	2023-09-28	NCT04825678
Eli Lilly	Galcanezumab	—	COMPLETED	2023-05-23	NCT05127486
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2023-04-04	NCT05264129
Novartis	Erenumab	—	COMPLETED	2023-02-23	NCT04084314
Amgen	Erenumab	—	COMPLETED	2023-01-18	NCT04265755
Amgen	Erenumab 70 mg	—	COMPLETED	2022-12-01	NCT03971071
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2022-08-31	NCT04041284
David True	Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]	—	COMPLETED	2022-01-10	NCT04461795
Amgen	AMG334	—	COMPLETED	2021-10-01	NCT03927144
Novartis	erenumab	—	COMPLETED	2021-07-05	NCT03977649
Eli Lilly	Galcanezumab	—	COMPLETED	2021-03-05	NCT04294147
Novartis	Erenumab	—	COMPLETED	2020-07-29	NCT03828539
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2017-05-09	NCT02191579
Depomed	Diclofenac Potassium for Oral Solution	—	COMPLETED	2016-02	NCT02287376
AbbVie	onabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2015-11	NCT01516892
Jiangsu Kanion Pharmaceutical Co., Ltd	Tianshu capsule	—	COMPLETED	2015-04	NCT02035111
AbbVie	botulinum toxin Type A	—	COMPLETED	2015-02	NCT02147561
AbbVie	OnabotulinumtoxinA	Acetylcholine Release Inhibitor [EPC]	COMPLETED	2014-09	NCT01833130
Tian Medical Inc.	Marcaine	—	COMPLETED	2014-02	NCT01709708
AstraZeneca	Zolmitriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2013-10	NCT01211145
Novartis	Aspirin, acetaminophen and caffeine	—	COMPLETED	2011-03	NCT01248468
Zogenix, Inc.	Sumatriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2010-04	NCT01016834
GSK	sumatriptan and naproxen sodium combination tablet	—	COMPLETED	2009-11	NCT00792636
Supernus Pharmaceuticals, Inc.	SPN-538	—	TERMINATED	2023-03-01	NCT04050293
H. Lundbeck A/S	Eptinezumab	—	TERMINATED	2023-02-17	NCT05284019
Amgen	Erenumab	—	TERMINATED	2021-07-28	NCT03912337
Vincent Martin, MD	Theramine (medical food/old drug)	—	TERMINATED	2014-12	NCT01944059

Showing 100 of 148 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
H. Lundbeck A/S	Eptinezumab	—	RECRUITING	2026-09-05	NCT04965675
Pfizer	Rimegepant	—	RECRUITING	2026-10-08	NCT06616194
Pfizer	Rimegepant	—	RECRUITING	2026-11-29	NCT06641466
Merz Therapeutics GmbH	Xeomin	Acetylcholine Release Inhibitor [EPC]	RECRUITING	2027-03	NCT07018700
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2027-05	NCT05125302
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2027-06	NCT06417775
H. Lundbeck A/S	Eptinezumab	—	RECRUITING	2027-07-06	NCT05897320
Merz Therapeutics GmbH	Xeomin	Acetylcholine Release Inhibitor [EPC]	RECRUITING	2027-10	NCT07018713
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2028-03	NCT05711394
H. Lundbeck A/S	Eptinezumab	—	RECRUITING	2028-04-30	NCT05164172
Pfizer	Rimegepant/BHV3000	—	RECRUITING	2029-01-09	NCT04649242
Pfizer	Rimegepant (PF-07899801)	—	RECRUITING	2030-07-31	NCT04743141
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	RECRUITING	2031-03	NCT06810505
Pfizer	Rimegepant	—	RECRUITING	2031-11-29	NCT05156398
Ipsen	Botulinum toxin type A	—	ACTIVE NOT RECRUITING	2026-05-27	NCT06047457
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-02	NCT06806293
Ipsen	Botulinum toxin type A	—	ACTIVE NOT RECRUITING	2026-05-21	NCT06047444
Eli Lilly	Galcanezumab	—	ACTIVE NOT RECRUITING	2025-12-10	NCT04616326
Amgen	Erenumab Dose 1	—	ACTIVE NOT RECRUITING	2025-11-19	NCT03836040
Eli Lilly	Galcanezumab	—	ACTIVE NOT RECRUITING	2025-11-14	NCT03432286
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-07-07	NCT06241313
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-04-28	NCT05748483
IntraBio Inc	N-Acetyl-L-Leucine	—	NOT YET RECRUITING	2027-08-01	NCT07221292
Dr George Medvedev	Eptinezumab	—	NOT YET RECRUITING	2025-12-30	NCT06428838
AbbVie	Atogepant 60 mg	—	COMPLETED	2025-10-20	NCT04686136
Pfizer	Rimegepant	—	COMPLETED	2025-08-25	NCT05810038
Teva Branded Pharmaceutical Products R&D LLC	Fremanezumab	—	COMPLETED	2025-08-15	NCT04530110
Pfizer	Zavegepant	—	COMPLETED	2025-05-30	NCT05989048
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2025-05-02	NCT05216263
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2025-03-01	NCT05861427
Amgen	Erenumab Dose 1	—	COMPLETED	2025-01-08	NCT03832998
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2024-11-29	NCT04464707
Axsome Therapeutics, Inc.	AXS-07 (meloxicam-rizatriptan)	—	COMPLETED	2024-11-27	NCT05550207
Eurofarma Laboratorios S.A.	Rizatriptan 10 mg + Naproxen 550mg	—	COMPLETED	2024-10-30	NCT04384367
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2024-10-01	NCT04921384
AbbVie	Atogepant 60 mg	—	COMPLETED	2024-06-11	NCT04437433
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2024-06-08	NCT05064371
Click Therapeutics, Inc.	—	—	COMPLETED	2024-05-21	NCT06004388
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2024-03-13	NCT04458857
Pfizer	Rimegepant 75mg Orally Disintegrating Tablets (ODT)	—	COMPLETED	2024-02-06	NCT05371652
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2024-01-31	NCT05458011
Pfizer	Rimegepant 25 MG	—	COMPLETED	2024-01-19	NCT05399459
Pfizer	Rimegepant	—	COMPLETED	2024-01-18	NCT05399485
Tian Medical Inc.	—	—	COMPLETED	2023-11-15	NCT03337620
RDC Clinical Pty Ltd	Palmitoylethanolamide sold as Levagen +	—	COMPLETED	2023-03-09	NCT05046522
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2023-01-16	NCT04406649
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2022-10-13	NCT04940390
AbbVie	Atogepant 60 mg	—	COMPLETED	2022-08-04	NCT04740827
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2022-05-23	NCT04772742
AbbVie	Ubrogepant 100 mg	—	COMPLETED	2022-04-19	NCT04492020
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2022-01-20	NCT04829747
AbbVie	Atogepant 30 mg	—	COMPLETED	2022-01-20	NCT03855137
Pfizer	Zavegepant (BHV-3500)	—	COMPLETED	2021-12-09	NCT04408794
Pfizer	Rimegepant	—	COMPLETED	2021-11-24	NCT04574362
Pfizer	Zavegepant	—	COMPLETED	2021-10-10	NCT04571060
Novartis	Erenumab	—	COMPLETED	2021-08-11	NCT03867201
Eli Lilly	Galcanezumab	—	COMPLETED	2021-07-27	NCT03963232
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2021-07-15	NCT04418765
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2021-03-31	NCT03939312
Otsuka Pharmaceutical Co., Ltd.	Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.	—	COMPLETED	2020-11-11	NCT04355117
IlDong Pharmaceutical Co Ltd	Lasmiditan 50mg	—	COMPLETED	2020-10-30	NCT04218162
Axsome Therapeutics, Inc.	AXS-07	—	COMPLETED	2020-09-22	NCT04068051
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2020-07-31	NCT03901482
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2020-07-08	NCT04152083
Impax Laboratories, LLC	ZNS	—	COMPLETED	2020-07-02	NCT03275922
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2020-06-19	NCT03777059
Otsuka Pharmaceutical Co., Ltd.	TEV-48125	—	COMPLETED	2020-06-16	NCT03303105
Eli Lilly	Lasmiditan	—	COMPLETED	2020-06-12	NCT03670810
AbbVie	Standard of Care (SOC) Migraine Preventive Medication	—	COMPLETED	2020-05-21	NCT03700320
Impel Pharmaceuticals	—	—	COMPLETED	2020-03-17	NCT03557333
Axsome Therapeutics, Inc.	AXS-07 (MoSEIC meloxicam and rizatriptan)	—	COMPLETED	2020-03-16	NCT04163185
Amgen	Erenumab	—	COMPLETED	2020-03-16	NCT03812224
Novartis	Erenumab	—	COMPLETED	2020-01-13	NCT03333109
Pfizer	Rimegepant	—	COMPLETED	2019-12-10	NCT03732638
Axsome Therapeutics, Inc.	AXS-07 (MoSEIC meloxicam and rizatriptan)	—	COMPLETED	2019-12-10	NCT03896009
Otsuka Pharmaceutical Co., Ltd.	TEV-48125	—	COMPLETED	2019-11-30	NCT03303079
Otsuka Pharmaceutical Co., Ltd.	TEV-48125	—	COMPLETED	2019-11-22	NCT03303092
Pfizer	Zavegepant	—	COMPLETED	2019-10-31	NCT03872453
Eli Lilly	Lasmiditan	—	COMPLETED	2019-08-20	NCT02565186
Eli Lilly	Galcanezumab	—	COMPLETED	2019-08-10	NCT02959190
Pfizer	Rimegepant	—	COMPLETED	2019-07-15	NCT03266588
Eli Lilly	Galcanezumab	—	COMPLETED	2019-06-19	NCT03559257
Zosano Pharma Corporation	M207 Microneedle System	—	COMPLETED	2019-05-17	NCT03282227
Pfizer	Rimegepant	—	COMPLETED	2018-10-08	NCT03461757
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2018-10-02	NCT03308968
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2018-08-02	NCT02873221
Teva Branded Pharmaceutical Products R&D, Inc.	Fremanezumab	—	COMPLETED	2018-06-06	NCT02638103
Allodynic Therapeutics, Inc	Naltrexone and Acetaminophen Combination	—	COMPLETED	2018-05-07	NCT03185143
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2018-04-02	NCT02848326
Alder Biopharmaceuticals, Inc.	ALD403 (Eptinezumab)	—	COMPLETED	2018-04	NCT02985398
Pfizer	Rimegepant	—	COMPLETED	2018-01-25	NCT03237845
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2018-01-25	NCT02867709
Pfizer	Rimegepant	—	COMPLETED	2018-01-21	NCT03235479
Novartis	AMG334 (70 mg) Pre-Filled Syringe (PFS)	—	COMPLETED	2018-01-18	NCT03096834
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2017-12-13	NCT02828020
BioDelivery Sciences International	DFN-15 Active	—	COMPLETED	2017-11	NCT03009019
BioDelivery Sciences International	DFN-15 Active	—	COMPLETED	2017-11	NCT03006276
Alder Biopharmaceuticals, Inc.	ALD403 (Eptinezumab)	—	COMPLETED	2017-11	NCT02974153
Eli Lilly	Lasmiditan 50 mg	—	COMPLETED	2017-06-30	NCT02605174
Pharmalyte Solutions LLC	MLD10	—	COMPLETED	2017-06	NCT02322333

Showing 61 of 61 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sichuan Purity Pharmaceutical Technology Co., Ltd.	PRT-064040 nasal spray	—	RECRUITING	2026-09	NCT07304518
AbbVie	MEDI0618	—	RECRUITING	2026-12-18	NCT06602479
Ipsen	IPN10200	—	RECRUITING	2027-01-31	NCT06625060
H. Lundbeck A/S	Lu AG09222	—	ACTIVE NOT RECRUITING	2026-01-16	NCT06323928
Kallyope Inc.	Elismetrep (K-304) Dose Level 1	—	COMPLETED	2025-08-11	NCT06848075
Manistee Therapeutics	MTX101	—	COMPLETED	2025-06-27	NCT06728553
Biohaven Therapeutics Ltd.	BHV-2100	—	COMPLETED	2025-03-24	NCT06603623
AEON Biopharma, Inc.	ABP-450	—	COMPLETED	2024-06-19	NCT04845178
Tonix Pharmaceuticals, Inc.	TNX-1900	—	COMPLETED	2023-10-08	NCT05679908
H. Lundbeck A/S	Lu AG09222	—	COMPLETED	2023-01-19	NCT05133323
Eli Lilly	LY3451838	—	COMPLETED	2022-11-09	NCT04498910
Cerecin	Tricaprilin	—	COMPLETED	2022-02-07	NCT04437199
Asarina Pharma	Sepranolone injection low dose	—	COMPLETED	2021-05-15	NCT04102995
Eli Lilly	Lasmiditan	—	COMPLETED	2020-06-08	NCT03962738
Lateral Pharma Pty Ltd	LAT8881	—	COMPLETED	2020-02-15	NCT04153409
Charleston Laboratories, Inc	Arm 1: CL-H1T	—	COMPLETED	2019-08-27	NCT03877718
AOBiome LLC	B244	—	COMPLETED	2019-06-17	NCT03488563
Eli Lilly	Galcanezumab	—	COMPLETED	2019-01-18	NCT02959177
Amgen	AMG 301	—	COMPLETED	2018-10-16	NCT03238781
Allodynic Therapeutics, Inc	Low-Dose Naltrexone and Acetaminophen Combination	—	COMPLETED	2018-07-26	NCT03194555
Allodynic Therapeutics, Inc	Naltrexone and Acetaminophen	—	COMPLETED	2018-02-08	NCT06245902
Allodynic Therapeutics, Inc	Naltrexone and Acetaminophen	—	COMPLETED	2018-02-08	NCT03061734
Amgen	Erenumab	—	COMPLETED	2017-09-25	NCT02630459
Amgen	Erenumab	—	COMPLETED	2017-05-26	NCT02174861
Upsher-Smith Laboratories	Sumatriptan 10 mg Nasal Spray	—	COMPLETED	2017-02-10	NCT02856802
Dr. Reddy's Laboratories Limited	DFN-11	—	COMPLETED	2016-04	NCT02571049
Alder Biopharmaceuticals, Inc.	ALD403	—	COMPLETED	2016-03	NCT02275117
Amgen	Erenumab	—	COMPLETED	2016-02-24	NCT02066415
Dr. Reddy's Laboratories Limited	DFN-15 Dose A (treatment A)	—	COMPLETED	2015-12-01	NCT02472418
Trigemina, Inc	TI-001	—	COMPLETED	2015-10	NCT01839149
Eli Lilly	Galcanezumab	—	COMPLETED	2015-08-19	NCT02163993
Teva Branded Pharmaceutical Products R&D, Inc.	LBR-101 High Dose	—	COMPLETED	2015-02-28	NCT02021773
Teva Branded Pharmaceutical Products R&D, Inc.	LBR-101 High Dose	—	COMPLETED	2015-01-31	NCT02025556
Achelios Therapeutics	ELS-M11	—	COMPLETED	2014-11	NCT02057315
Amgen	Erenumab	—	COMPLETED	2014-09-25	NCT01952574
Eli Lilly	LY2951742	—	COMPLETED	2013-07	NCT01625988
AbbVie	MK-1602	—	COMPLETED	2012-12-01	NCT01613248
AbbVie	MK-1602	—	COMPLETED	2012-11	NCT01657370
Merck	MK-6096	—	COMPLETED	2012-10-03	NCT01513291
Pfizer	Rimegepant	—	COMPLETED	2012-05	NCT01430442
Duramed Research	91-day Levonorgestrel Oral Contraceptive	—	COMPLETED	2011-08	NCT00781456
Novartis	BGG492	—	COMPLETED	2010-08	NCT00892203
XenoPort, Inc.	GSK1838262	—	COMPLETED	2010-06	NCT00742209
Bial - Portela C S.A.	ESL 1200 mg	—	COMPLETED	2010-06	NCT01820559
NeurAxon Inc.	NXN-188	—	COMPLETED	2010-03	NCT00920686
Eli Lilly	Lasmiditan	—	COMPLETED	2010-02	NCT00883051
NeurAxon Inc.	NXN-188	—	COMPLETED	2010-02	NCT00959751
Merck	ibuprofen	Nonsteroidal Anti-inflammatory Drug [EPC]	COMPLETED	2009-08-24	NCT00758836
Capnia, Inc.	Nasal CO2	—	COMPLETED	2009-06	NCT00690716
Boehringer Ingelheim	BI 44370 TA Low Dose	—	COMPLETED	2009-05	NCT00751803
Merck	MK3207- 2.5 mg	—	COMPLETED	2009-01	NCT00712725
Kallyope Inc.	K-645 dose level 1	—	TERMINATED	2025-11-07	NCT07116499
AEON Biopharma, Inc.	ABP-450	—	TERMINATED	2024-07-31	NCT05016661
Capnia, Inc.	Nasal Carbon Dioxide	—	TERMINATED	2013-04	NCT01253915
Eli Lilly	LY2300559	—	TERMINATED	2012-04	NCT01184508
Addex Pharma S.A.	ADX10059	—	TERMINATED	2010-01	NCT00820105
Merck	Telcagepant 140 mg	—	TERMINATED	2009-05-20	NCT00797667
Eli Lilly	LY2590443	—	TERMINATED	2009-05	NCT00804973
Allodynic Therapeutics, Inc	Stage 1: Naltrexone/Acetaminophen	—	WITHDRAWN	2025-12-02	NCT05685225
Novartis	BGG492	—	WITHDRAWN	2016-11	NCT01617941
D-Pharm Ltd.	DP-VPA	—	WITHDRAWN	2009-06	NCT00640965

Showing 57 of 57 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pfizer	Zavegepant	—	RECRUITING	2027-08-12	NCT06995729
Pfizer	ODT2 Test formulation	—	NOT YET RECRUITING	2026-09-07	NCT07594769
Sichuan Purity Pharmaceutical Technology Co., Ltd.	PRT-064040 nasal spray	—	COMPLETED	2025-09-08	NCT07016516
H. Lundbeck A/S	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2025-07-11	NCT06578585
Vaxxinity, Inc.	UB-313	—	COMPLETED	2023-10-06	NCT05477095
Humanis Saglık Anonim Sirketi	Ibuprofen/ Paracetamol tablets	—	COMPLETED	2023-09-14	NCT06180070
H. Lundbeck A/S	Lu AG09222	—	COMPLETED	2022-10-30	NCT05304910
H. Lundbeck A/S	Eptinezumab	—	COMPLETED	2022-10-20	NCT04537429
Amgen	AMG 334 Dose 1	—	COMPLETED	2021-11-23	NCT03499119
Zosano Pharma Corporation	Treatment A: M207 3.8 mg "MiniMac"	—	COMPLETED	2021-09-02	NCT04969497
AbbVie	Atogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2021-06-18	NCT04818515
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2021-06-04	NCT05337254
SK Chemicals Co., Ltd.	Topiramate	Cytochrome P450 3A4 Inducers [MoA]	COMPLETED	2020-10-06	NCT04401137
H. Lundbeck A/S	ALD1910	—	COMPLETED	2020-08-19	NCT04197349
Eli Lilly	Lasmiditan	—	COMPLETED	2020-01-19	NCT03988088
AbbVie	Ubrogepant	Calcitonin Gene-related Peptide Receptor Antagonist [EPC]	COMPLETED	2019-12-23	NCT04179474
Zosano Pharma Corporation	M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches)	—	COMPLETED	2019-06-28	NCT03978403
Zosano Pharma Corporation	A: M207 3.8mg, 30 min, upper arm	—	COMPLETED	2018-11-20	NCT03708744
Satsuma Pharmaceuticals, Inc.	Dihydroergotamine	—	COMPLETED	2018-11-07	NCT03874832
Sorrento Therapeutics, Inc.	Sumatriptan Succinate Oral Tablet	—	COMPLETED	2018-03-28	NCT03229798
Eli Lilly	Lasmiditan	—	COMPLETED	2018-01-15	NCT03247790
Impel Pharmaceuticals	Dihydroergotamine Mesylate (DHE)	—	COMPLETED	2017-12-01	NCT03401346
Amgen	Erenumab	—	COMPLETED	2017-09-28	NCT02542605
Dr. Reddy's Laboratories Limited	DFN-15 (fasted)	—	COMPLETED	2017-08-22	NCT03282838
Eli Lilly	lasmiditan 200 mg	—	COMPLETED	2017-07-17	NCT03040479
Eli Lilly	Lasmiditan	—	COMPLETED	2017-06-08	NCT03012334
Eli Lilly	Lasmiditan	—	COMPLETED	2017-06-02	NCT03009162
Eli Lilly	lasmiditan 200 mg	—	COMPLETED	2017-04-13	NCT03076970
Acorda Therapeutics	CVT-427 (zolmitriptan inhalation powder)	—	COMPLETED	2016-12	NCT02905227
Amgen	Erenumab	—	COMPLETED	2016-09-09	NCT02792517
Acorda Therapeutics	zolmitriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2015-12	NCT02609945
Cefaly Technology	—	—	COMPLETED	2015-10	NCT02411513
Eli Lilly	LY2951742	—	COMPLETED	2015-01	NCT02104765
NuPathe Inc.	PROT-CL-NP101-015.01	—	COMPLETED	2014-11	NCT02684409
Amgen	AMG 333	—	COMPLETED	2014-09	NCT01953341
Amgen	Erenumab	—	COMPLETED	2014-07-10	NCT01723514
Alder Biopharmaceuticals, Inc.	ALD403	—	COMPLETED	2013-12	NCT01772524
Amgen	Erenumab	—	COMPLETED	2013-03-27	NCT01688739
Pfizer	PF-04427429	—	COMPLETED	2013-01	NCT01511497
Alder Biopharmaceuticals, Inc.	ALD403	—	COMPLETED	2012-12	NCT01579383
Pfizer	BMS-927711 (CGRP Antagonist)	—	COMPLETED	2012-09	NCT01445067
Eli Lilly	LY2951742	—	COMPLETED	2012-04	NCT01337596
Optinose US Inc.	Sumatriptan	Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]	COMPLETED	2012-02	NCT01507610
Merck	telcagepant	—	COMPLETED	2011-07-26	NCT01315847
AstraZeneca	Rapimelt	—	COMPLETED	2010-10	NCT01085123
GSK	This is a pharmacokinetic study (Treximet)	—	COMPLETED	2009-09-10	NCT00989625
NuPathe Inc.	Sumatriptan succinate	5-HT1B/5-HT1D	COMPLETED	2009-09	NCT00723983
Boehringer Ingelheim	BI 44370 TA tablet	—	COMPLETED	2009-03	NCT00743015
NuPathe Inc.	NP101 Sumatriptan Iontophoretic Transdermal Patch	—	COMPLETED	2008-07	NCT00720018
GSK	TREXIMA™	—	COMPLETED	2008-06-14	NCT00875784
Merck	MK0974 Ethanolate formulation	—	COMPLETED	2008-05	NCT00965887
Merck	MK0974 tablet	—	COMPLETED	2008-05	NCT00966030
Trevena Inc.	Part A: TRV250-20mg/ml	—	TERMINATED	2020-02-17	NCT04201080
Amgen	AMG 333	—	TERMINATED	2014-10	NCT02132429
Pfizer	PF-05180999	—	TERMINATED	2014-04	NCT01981499
Ethicon, Inc.	—	—	TERMINATED	2013-07	NCT01855672
Pfizer	PF-05180999 Tablets	—	WITHDRAWN	2015-01	NCT01981486

Novel Drugs by Company (New molecular entities)

Eli Lilly 2 drugs

Pfizer 2 drugs

ZAVEGEPANT HYDROCHLORIDE

Amgen 1 drug

Teva 1 drug

Lundbeck Seattle BioPharmaceuticals, Inc. 1 drug

AbbVie 1 drug

Reformulations (21 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.